Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lorrain

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
ACS Chemical Neuroscience|January 24, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment EfficacyThomas O Schrader, Kym I Lorrain, Didier Bagnol, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Scientific Reports|May 8, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
British Journal of Pharmacology|July 24, 2010
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelJ S Swaney, C Chapman, L D Correa, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2011
Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonistNicholas Stock, Deborah Volkots, Karin Stebbins, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2009
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitisBrian A Stearns, Christopher Baccei, Gretchen Bain, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Clinical Pharmacology and Therapeutics|February 26, 2010
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.
European Journal of Pharmacology|June 4, 2010
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
ACS Chemical Neuroscience|January 24, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment EfficacyThomas O Schrader, Kym I Lorrain, Didier Bagnol, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Scientific Reports|May 8, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
British Journal of Pharmacology|July 24, 2010
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelJ S Swaney, C Chapman, L D Correa, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2011
Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonistNicholas Stock, Deborah Volkots, Karin Stebbins, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2009
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitisBrian A Stearns, Christopher Baccei, Gretchen Bain, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Clinical Pharmacology and Therapeutics|February 26, 2010
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.
European Journal of Pharmacology|June 4, 2010
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Pageof 7